Spots Global Cancer Trial Database for urothelial carcinoma of the bladder
Every month we try and update this database with for urothelial carcinoma of the bladder cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer | NCT05241340 | Urothelial Carc... | Sasanlimab Stereotactic Bo... Radical Cystect... | 18 Years - | The Methodist Hospital Research Institute | |
| TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer | NCT04073160 | Bladder Cancer | Tremelimumab Durvalumab Bladder radiati... Intravesicular ... | 18 Years - | Duke University | |
| An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma | NCT04586244 | Urothelial Carc... | retifanlimab epacadostat INCAGN02385 INCAGN02390 | 18 Years - | Incyte Corporation | |
| Initial Evaluation of a Telomerase-based Circulating Tumor Cell Assay in Bladder Cancer Cohorts | NCT02246738 | Urothelial Carc... | Blood Collectio... | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma | NCT04586244 | Urothelial Carc... | retifanlimab epacadostat INCAGN02385 INCAGN02390 | 18 Years - | Incyte Corporation | |
| Adjuvant Proton Therapy or IMRT for the Treatment of Bladder Cancer | NCT01520038 | Urothelial Carc... | Proton therapy IMRT | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Initial Evaluation of a Telomerase-based Circulating Tumor Cell Assay in Bladder Cancer Cohorts | NCT02246738 | Urothelial Carc... | Blood Collectio... | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| AN0025 and Pembrolizumab Combination in Advanced Solid Tumors | NCT04432857 | Triple-negative... NSCLC, Squamous... Urothelial Carc... Microsatellite ... Cervical Cancer | AN0025 Pembrolizumab | 18 Years - | Adlai Nortye Biopharma Co., Ltd. | |
| Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer | NCT05241340 | Urothelial Carc... | Sasanlimab Stereotactic Bo... Radical Cystect... | 18 Years - | The Methodist Hospital Research Institute | |
| Adjuvant Proton Therapy or IMRT for the Treatment of Bladder Cancer | NCT01520038 | Urothelial Carc... | Proton therapy IMRT | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN) | NCT02710734 | Urothelial Carc... | Methotrexate Vinblastine Doxorubicin Cisplatin Intensity modul... Transurethral R... 5-FU Mitomycin C | 18 Years - | Fox Chase Cancer Center | |
| Adjuvant Proton Therapy or IMRT for the Treatment of Bladder Cancer | NCT01520038 | Urothelial Carc... | Proton therapy IMRT | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Initial Evaluation of a Telomerase-based Circulating Tumor Cell Assay in Bladder Cancer Cohorts | NCT02246738 | Urothelial Carc... | Blood Collectio... | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| AN0025 and Pembrolizumab Combination in Advanced Solid Tumors | NCT04432857 | Triple-negative... NSCLC, Squamous... Urothelial Carc... Microsatellite ... Cervical Cancer | AN0025 Pembrolizumab | 18 Years - | Adlai Nortye Biopharma Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
